CIBC Innovation Banking Provides ContactMonkey with Growth Capital Financing
TORONTO--(BUSINESS WIRE)--CIBC Innovation Banking announced today that it has provided growth capital financing to ContactMonkey, a portfolio company of Updata Partners. The company will use the financing to continue growing its reach globally and expand product offerings to new and existing customers around the world.
ContactMonkey is an internal email platform used by over 10,000 communicators worldwide. The platform integrates with commonly used applications such as Microsoft Outlook, Microsoft Teams and major human resource information software (HRIS) platforms, helping users engage employees across their organization.
'We are excited to partner with the CIBC Innovation Banking team to support our next phase of growth,' said David Dean, CFO at ContactMonkey. 'This agreement provides us added flexibility and opportunity as we continue to enable more organizations to deliver engaging and effective communications worldwide.'
'We are excited to support the ContactMonkey team as it continues its growth and leadership within the internal communications space,' said Ab Makalo, Director, CIBC Innovation Banking. 'Our team looks forward to helping ContactMonkey scale as it expands its robust offering globally.'
About CIBC Innovation Banking
CIBC Innovation Banking has 25 years of specialized experience in growth-stage tech and life science companies across North America – a longer track record than most banks. CIBC Innovation Banking now has over $11 billion in funds managed including life sciences, health care, cleantech companies, investors, and entrepreneurs, and has assisted over 700 venture and private equity-backed businesses over the past six and a half years. The bank operates out of 14 global locations in San Francisco, Menlo Park, New York, Toronto, London, Austin, Boston, Chicago, Seattle, Vancouver, Montreal, Atlanta, Reston, and Durham. Connect with us today to start the conversation. https://www.innovationbanking.cibc.com/
About ContactMonkey
ContactMonkey is the internal email platform trusted by over 10,000 internal communicators worldwide. Reach employees at every corner of your organization, ensuring that essential company announcements, life-saving alerts, and critical updates are delivered promptly. With data-driven insights, understand what truly resonates with your employees, and refine your communication strategies for optimal engagement.
Build a productive and engaged workforce with ContactMonkey. Learn more at
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
GWM Returns After a Decade to Clinch Taklimakan Rally Production Title
AKSU CITY, China, June 06, 2025--(BUSINESS WIRE)--At the final stage of the 2025 Taklimakan Rally, GWM reclaimed the Production Class championship after a decade, once again demonstrating its dominance in the off-road segment. This year, GWM competed with both internal combustion and new energy vehicles, not only continuing the legacy of its legendary diesel-powered models, but also setting a new performance benchmark in the electrified off-road category with its Hi4 series PHEV technology—raising the global profile of Chinese automotive brands in the world of rally racing. A Taklimakan Rally standout, the GWM HAVAL H9 Diesel dominated the T2.1 production class with its 2.4T engine, 9-speed automatic transmission, and triple locking differentials. Its TOD intelligent four-wheel-drive system and electronic axle locks delivered optimal torque across tough terrain. The GWM TANK Hi4 Team claimed the T2.E Production New Energy Manufacturer Championship, showcasing the strength of PHEV technology in extreme off-road conditions. Powered by GWM's groundbreaking Hi4 system—the world's first dual-motor distributed 4WD—it delivers a unique balance of 4WD performance and 2WD efficiency. From winning the championship in 2015 to the full-scale breakthrough of Hi4-PHEV technology in 2025, GWM has spent a decade evolving from an internal combustion engine performance benchmark to a leader in new energy off-road mobility. In this year's Taklimakan Rally, GWM HAVAL, GWM TANK, and GWM POER product lineups collectively secured 12 honors, including the Production Class Manufacturer's Cup, overall championship titles, and multiple stage victories. With the mass production of Hi4 technology in models like the GWM TANK 300 Hi4-T and TANK 500 Hi4-Z, GWM is redefining off-road culture for the new energy era. This advanced system brings four-wheel-drive performance at two-wheel-drive prices, and will soon expand across more models—making off-road capability more accessible than ever. This championship victory marks the maturation of GWM's "All-powertrains, All-scenarios, All Users" technology strategy. By testing its mass-produced vehicles on the rally field, GWM leverages its championship-grade quality to expand its presence in the global off-road market. Looking ahead, the company will continue to anchor its development in user needs, delivering more products that can endure extreme challenges—driving the rise of "intelligent manufacturing in China" across the world's toughest landscapes. View source version on Contacts Carol Wang, globalmarketing@
Associated Press
12 minutes ago
- Associated Press
GWM Returns After a Decade to Clinch Taklimakan Rally Production Title
AKSU CITY, China--(BUSINESS WIRE)--Jun 6, 2025-- At the final stage of the 2025 Taklimakan Rally, GWM reclaimed the Production Class championship after a decade, once again demonstrating its dominance in the off-road segment. This year, GWM competed with both internal combustion and new energy vehicles, not only continuing the legacy of its legendary diesel-powered models, but also setting a new performance benchmark in the electrified off-road category with its Hi4 series PHEV technology—raising the global profile of Chinese automotive brands in the world of rally racing. A Taklimakan Rally standout, the GWM HAVAL H9 Diesel dominated the T2.1 production class with its 2.4T engine, 9-speed automatic transmission, and triple locking differentials. Its TOD intelligent four-wheel-drive system and electronic axle locks delivered optimal torque across tough terrain. The GWM TANK Hi4 Team claimed the T2.E Production New Energy Manufacturer Championship, showcasing the strength of PHEV technology in extreme off-road conditions. Powered by GWM's groundbreaking Hi4 system—the world's first dual-motor distributed 4WD—it delivers a unique balance of 4WD performance and 2WD efficiency. From winning the championship in 2015 to the full-scale breakthrough of Hi4-PHEV technology in 2025, GWM has spent a decade evolving from an internal combustion engine performance benchmark to a leader in new energy off-road mobility. In this year's Taklimakan Rally, GWM HAVAL, GWM TANK, and GWM POER product lineups collectively secured 12 honors, including the Production Class Manufacturer's Cup, overall championship titles, and multiple stage victories. With the mass production of Hi4 technology in models like the GWM TANK 300 Hi4-T and TANK 500 Hi4-Z, GWM is redefining off-road culture for the new energy era. This advanced system brings four-wheel-drive performance at two-wheel-drive prices, and will soon expand across more models—making off-road capability more accessible than ever. This championship victory marks the maturation of GWM's 'All-powertrains, All-scenarios, All Users' technology strategy. By testing its mass-produced vehicles on the rally field, GWM leverages its championship-grade quality to expand its presence in the global off-road market. Looking ahead, the company will continue to anchor its development in user needs, delivering more products that can endure extreme challenges—driving the rise of 'intelligent manufacturing in China' across the world's toughest landscapes. View source version on Carol Wang,[email protected] KEYWORD: CHINA ASIA PACIFIC INDUSTRY KEYWORD: SPORTS EV/ELECTRIC VEHICLES AUTOMOTIVE AUTOMOTIVE MANUFACTURING MOTOR SPORTS VEHICLE TECHNOLOGY MANUFACTURING OFF-ROAD TRUCKS & SUVS SOURCE: GWM Copyright Business Wire 2025. PUB: 06/06/2025 06:18 AM/DISC: 06/06/2025 06:17 AM
Associated Press
12 minutes ago
- Associated Press
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jun 6, 2025-- Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo 1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data 1. Specifically, 76.3% of patients treated with sibeprenlimab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group. 1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenlimab compared to 5.4% treated with placebo. Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 2. Sibeprenlimab is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation 3,4,5,6. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home. 'We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials,' said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. 'Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease.' The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be completed in early 2026. Further prespecified and exploratory analyses of the data will be conducted to determine the full potential of sibeprenlimab for the treatment of IgAN 1. 'The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo. These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date. The study enrolled a diverse patient population reflective of the disease epidemiology,' said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham. 'The safety data emerging from VISIONARY is reassuring and adds to our existing knowledge about sibeprenlimab's safety profile from prior programs. This is very exciting news for patients and adds a therapeutic option with a novel mechanism of action potentially targeting the immunologic pathogenesis of IgAN.' About the VISIONARY Study The VISIONARY study is the largest IgAN trial to date, and is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 510 adult patients with IgAN who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo 1. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over ~24 months 1. About Sibeprenlimab Sibeprenlimab (formerly VIS649) was designed and engineered by Visterra, Inc., a wholly owned subsidiary of Otsuka. Pre-clinical and early-stage trials of sibeprenlimab were also conducted by Visterra. Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit process. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Decreased immune complex formation should result in diminished deposition in the kidney, and reduced proteinuria and kidney inflammation 8. By reducing the production of Gd-IgA1, sibeprenlimab may help slow kidney damage and progression toward ESKD 3,4,5,6. By inhibiting APRIL, sibeprenlimab may help address one of the IgAN-specific drivers for nephron loss. About IgAN and APRIL IgAN is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to ESKD over the lifetime of most patients 9,10,11. IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys. IgAN can lead to progressive loss of kidney function and, eventually, ESKD, imposing a significant burden on patients 10. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition. Continued research in the disease remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients 5. APRIL, a cytokine in the tumor necrosis factor (TNF) family, is integral to the pathogenesis and progression of IgAN. It promotes the survival and class switching of B cells to produce IgA, particularly the pathogenic galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes in the kidneys 5. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a 'big venture' company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024. All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at About Visterra Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision biologics-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting kidney diseases, immunologically-driven diseases and infectious diseases. Visterra is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, visit References View source version on CONTACT: Contacts for MediaOtsuka in the Murphy Corporate Communications Otsuka America Pharmaceutical, Inc. [email protected]+1 609 249 7262Otsuka in JapanJeffrey Gilbert Leader, Pharmaceutical PR Otsuka Pharmaceutical Co., Ltd. [email protected]+81 3 6361 7379 KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC NEW JERSEY INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS OTHER HEALTH SOURCE: Otsuka Pharmaceutical Co., Ltd. Copyright Business Wire 2025. PUB: 06/06/2025 06:00 AM/DISC: 06/06/2025 05:58 AM
